Acute ischemic stroke
Conditions
Interventions
Observation group:Individualized temperature health risk warning and stroke secondary prevention risk factor management information were received through mobile phone applications.
Sponsors
Xuanwu Hospital Capital Medical University
Eligibility
Sex/Gender
All
Age
40 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1 Age >= 40 years old, gender not limited; 2 Acute ischemic stroke patients who have been hospitalized within 2 weeks of onset, where the onset time refers to the time when the stroke symptoms occurred or the last known normal time of the patient (when it is a post-awakening stroke or due to aphasia, consciousness disorder, etc., and the time of symptom occurrence cannot be accurately obtained); 3 Within 2 weeks after the onset, confirmed to meet the diagnostic criteria for ischemic stroke by brain CT or MRI; 4 Local permanent residents (residence time >= 6 months); 5 Voluntary participants in the trial with high compliance and able to sign the informed consent form; 6 Patients with smart phones or other smart devices. Only those who meet all the above criteria can be included in the study.
Exclusion criteria
Exclusion criteria: 1 Patients diagnosed with other cerebrovascular diseases (such as hemorrhagic stroke, transient ischemic attack, cerebral venous sinus thrombosis, etc.) or non-cerebrovascular diseases; 2 Pregnant or lactating women who are known, or those whose pregnancy test results were positive before the random grouping; 3 Patients with other diseases that may affect participation in the trial (such as refractory hypertension, severe aphasia, etc.); 4 Patients receiving mental/psychological treatments that may contaminate the results; 5 Patients with an expected survival time of less than 1 year (such as those with malignant tumors, severe heart or lung diseases, etc.); 6 Patients who have already participated in other interventional clinical studies that may affect the outcome assessment; 7 Other situations where the investigators consider the patient not suitable for participation in this study or may pose significant risks to the patient (such as cognitive impairment that makes it impossible to understand and/or comply with the study procedures and/or follow-up). If any of the above exclusion criteria are met, the patient will not be included in this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Usability evaluation; | — |
Secondary
| Measure | Time frame |
|---|---|
| Retention;Auxiliary examination ( blood pressure, electrocardiogram, laboratory examination ( blood routine, urine routine, blood biochemistry, coagulation routine, etc. ) ;Environmental Risk Perception Quantitative Assessment Questionnaire;Health literacy scale for stroke patients;Recurrence risk perception assessment scale for stroke patients;Demographic data ( age, gender, height, weight, occupation, income, etc. );Previous disease history ( previous history of stroke, hypertension, hyperlipidemia, atrial fibrillation, coronary heart disease, diabetes, etc. );Previous medication history ( antiplatelet therapy, lipid-lowering drugs, antihypertensive drugs, etc. );Family history ( cerebrovascular disease history, cardiovascular disease history, etc. );Baseline data ( duration from onset to admission, duration from onset to reperfusion treatment, admission diagnosis, infarct location ( frontal lobe, temporal lobe, parietal lobe, etc. ), mRS score, NIHSS score, imaging data ( CT / MRI ), etc. );Treatment status ( whether thrombolysis / thrombectomy, types of thrombolytic drugs, doses of thrombolytic drugs, whether single-agent antiplatelet therapy / dual antiplatelet therapy, types of monoclonal antibodies / dual antiplatelet drugs, doses of monoclonal antibodies / dual antiplatelet drugs, antihypertensive drugs, lipid-lowering drugs, hypoglycemic drugs, neurotrophic drugs, other drugs );After treatment ( NIHSS score 24 hours after treatment, mRS score after treatment );Discharge data ( stroke TOAST classification, discharge mRS score, discharge NIHSS score, discharge BI score, EQ-5D-5L score, discharge diagnosis ).;Medication ( drug type, drug dose );Adverse events or serious adverse events;Neurological function recovery ( mRS score );Quality of life ( EQ-5D-5L ); | — |
Countries
China
Contacts
Public ContactHao Junwei
Xuanwu Hospital Capital Medical University
Outcome results
None listed